Literature DB >> 11985914

Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy.

Kathy A Crispell1, Emily L Hanson, Kelly Coates, Warren Toy, Ray E Hershberger.   

Abstract

OBJECTIVES: This study evaluated the role of clinical rescreening of family members at risk for familial dilated cardiomyopathy (FDC).
BACKGROUND: Familial dilated cardiomyopathy is a genetic cardiomyopathy that usually is transmitted in an autosomal dominant pattern and may underlie from one-quarter to one-half of idiopathic dilated cardiomyopathy (IDC) diagnoses. Thus, FDC may present with advanced heart failure (HF) or sudden cardiac death (SCD). Because FDC may respond to medical intervention, we have previously recommended that screening of first-degree relatives (parents, siblings, children) of patients diagnosed with IDC be undertaken to rule out FDC, and that with a diagnosis of FDC in the kindred, unaffected but at-risk family members be rescreened every three to five years. METHODS; Follow-up screening (history, examination, electrocardiogram, echocardiography) of a large family with FDC was performed six years after initial screening. Of 68 family members who underwent rescreening, two (one with left ventricular enlargement only, one with a left bundle branch block) presented with advanced HF and SCD, respectively. Two additional subjects, asymptomatic at initial screening, were also affected with FDC at follow-up.
CONCLUSIONS: Considerable vigilance for disease presentation and progression is indicated in at-risk members of a kindred with FDC, especially those with incipient FDC.

Entities:  

Mesh:

Year:  2002        PMID: 11985914     DOI: 10.1016/s0735-1097(02)01788-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

1.  A novel mutation of the LMNA gene in a family with dilated cardiomyopathy, conduction system disease, and sudden cardiac death of young females.

Authors:  Wenting Chen; Jianhua Huo; Aiqun Ma; Ling Bai; Ping Liu
Journal:  Mol Cell Biochem       Date:  2013-06-22       Impact factor: 3.396

2.  Familial dilated cardiomyopathy. Clinical and genetic characteristics.

Authors:  A Serio; N Narula; T Kodama; V Favalli; E Arbustini
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

3.  Identification of novel mutations in RBM20 in patients with dilated cardiomyopathy.

Authors:  Duanxiang Li; Ana Morales; Jorge Gonzalez-Quintana; Nadine Norton; Jill D Siegfried; Mark Hofmeyer; Ray E Hershberger
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

Review 4.  Dilated Cardiomyopathy: Genetic Determinants and Mechanisms.

Authors:  Elizabeth M McNally; Luisa Mestroni
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 5.  Familial cardiomyopathies: significant causes of heart failure.

Authors:  Kathy A Crispell
Journal:  Curr Cardiol Rep       Date:  2003-05       Impact factor: 2.931

6.  Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery.

Authors:  Krishna G Aragam; Mark Chaffin; Rebecca T Levinson; Gregory McDermott; Seung-Hoan Choi; M Benjamin Shoemaker; Mary E Haas; Lu-Chen Weng; Mark E Lindsay; J Gustav Smith; Christopher Newton-Cheh; Dan M Roden; Barry London; Quinn S Wells; Patrick T Ellinor; Sekar Kathiresan; Steven A Lubitz
Journal:  Circulation       Date:  2018-11-11       Impact factor: 29.690

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.